Especially diseases of the cardiovascular system in patients with severe and medium-severe plaque psoriasis

Abstract


Background. Psoriasis is a chronic inflammatory disease that associated with a decrease in life expectancy mostly due to cardiovascular disease. But prevalence of cardiovascular comorbidity in psoriasis patients has limited data. Objectives. To compare the prevalence of cardiovascular comorbidity in a hospital-treated cohort patients with severe psoriasis and psoriatic arthritis. Methods. 890 patients (M. - 516/F. - 347) with severe plaque psoriasis mean duration 25.7 ± 16.6 years, mean age of patients were 51.9 ± 11.6 years accordingly were included. Psoriasis patients with cardiovascular disease, including coronary heart disease, arterial hypertension, atherosclerosis and cerebrovascular accident were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010-2015 years. M ± m, t-test, (%) were calculated. All p < 0.05 were considered to indicate statistical significance. Results. Male and Female patients were at the same age. 303 out of 890 patients (34.0%) had psoriatic arthritis, 587 out of 890 patients (66.0%) had severe plaque psoriasis with mean PASI 49.4 ± 0.5. 516 out of 890 patients (59.0%) had cardiovascular disease. Cardiovascular disease coding as I 00-I 99 were found significantly often in patients with psoriatic arthritis compare to patients with psoriasis - in 206 out of 303 patients (68.2%) and in 310 out of 587 patients (52.8%) accordingly (p < 0.05). Arterial hypertension coding as I 10-I 15 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 206 out of 303 patients (68.2%) and in 310 out of 587 patients (52.8%) accordingly (p < 0.05). Coronary heart disease and atherosclerosis coding as I 70 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 129 out of 303 patients (42.7%) and in 205 out of 587 patients (34.9%) accordingly (p < 0.05). Cerebrovascular accident coding as I 65 - I 66 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 50 out of 303 patients (16.6%) and in 64 out of 587 patients (10.9%) accordingly. Conclusions. Psoriatic arthritis and cardiovascular comorbidities are common for hospital-treated cohort patients. Patients with severe plaque psoriasis and psoriatic arthritis tend to suffer from cardiovascular disease and arterial hypertension.


About the authors

N V Batkaeva

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Email: nbatkaeva.derm@yandex.ru

PhD, assistant professor, Faculty of advanced training of medical workers of the Peoples’ Friendship University of Russia (RUDN University)

E A Batkaev

Peoples’ Friendship University of Russia (RUDN University)

Email: nbatkaeva.derm@yandex.ru

M M Gitinova

Peoples’ Friendship University of Russia (RUDN University)

Email: nbatkaeva.derm@yandex.ru

E N Malyarenko

Peoples’ Friendship University of Russia (RUDN University)

Email: nbatkaeva.derm@yandex.ru

A I Golovinov

Treatment and Rehabilitation Clinical Center of the Ministry of Defense of the Russian Federation

Email: nbatkaeva.derm@yandex.ru

References

  1. Machado-Pinto J.M., Diniz M.S., Bavoso N.C. Psoriasis: new comorbidities. An Bras Dermatol. 2016;91(1):08—16.
  2. Nawaf AL-MUTAIRI, Shahat AL-FARAG, Ahmed AL-MUTAIRI, Mazen AL-SHILTAWY. Comorbidities associated with psoriasis: An experience from the Middle East. Journal of dermatology. 2010; 37: 146—155.
  3. Gulliver W.P. Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, 30 September — 5 October 2007, Buenos Aires, Argentina.
  4. O’Reilly D.D. Rahman P. Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):623—42. doi: 10.1016/j.rdc.2015.07.002.
  5. Egeberg А., Mallbris L., Warren R.B. et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. British Journal of Dermatology. (2016) 175, pp. 487—492. doi: 10.1111/bjd.14528.
  6. Puzyrev V.P. Genetic basis of comorbidity in humans. Genetics. 2015. Vol. 51. No. 4. P. 491—502. doi: 10.7868/S0016675815040098
  7. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus:a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84—91. doi: 10.1001/2013.jamadermatol.406.
  8. Horreau C, Pouplard C, Brenaut E. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013 Aug; 27 Suppl 3:12—29. doi: 10.1111/jdv.12163.
  9. Dogan S, Atakan N. Psoriasis: A Disease of Systemic Inflammation with Comorbidities. In: Lima H, editor. Psoriasis — Types, Causes and Medication. InTech; 2013. http://www.intechopen.com/books/psoriasis-types-causes-and-medication/psoriasis-a-disease-of-systemic-inflammation-with-comorbidities.
  10. Jing-Ji Jin, San-Wu Zeng. Association between psoriasis and metabolic syndrome: a meta-analysis from 12 case control studies. Int J Clin Exp Med. 2016;9(9):17933—17939.
  11. Spehr C, Reich K, Mrowietz U, Radtke MA, ThaciD, Rustenbach SJ, Augustin M. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015; 307(10): 875—883.
  12. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1-6.
  13. Roubille C, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480—489. doi: 10.1136/annrheumdis-2014-206624.
  14. Oliveira MFSP, Rocha BO, Duarte GV Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015; 90(1):09—20. DOI: http://dx.doi.org/10.1590/abd1806-4841.20153038.
  15. Armstrong AW. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? JAMA. 2013 May 15;309(19):2043—4. doi: 10.1001/jama.2013.4695.
  16. Wang Y, Gao H, Loyd CM, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012 Aug;132(8):2067—75. doi: 10.1038/jid.2012.112.
  17. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct; 21(10):874—88.

Statistics

Views

Abstract - 328

PDF (Russian) - 414

Cited-By


PlumX

Dimensions


Copyright (c) 2018 Batkaeva N.V., Batkaev E.A., Gitinova M.M., Malyarenko E.N., Golovinov A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies